San Diego-based Companion Medical said the funds are slated to help pursue FDA 510(k) clearance for its Bluetooth-enabled insulin pen and connected smartphone app.
“Lilly is focused on delivering the broadest portfolio of diabetes treatments in the industry, including innovative delivery methods to advance the treatment of diabetes. Companion’s smart pen and app represent innovation that could one day fill a gap for millions of people with diabetes,” Eli Lilly vice president for delivery & device R&D Divakar Ramakrishnan said in a prepared statement.
The company is developing an insulin injecting pen that connects to smartphones via bluetooth and sends data back, tracking insulin dosage and timing, the company said. The app allows patients to track and calculate doses, and set alarms for future doses.
“We are very excited to have Lilly as the lead investor in our series B financing. Lilly is a global leader in insulin, as well as other medicines and devices in the international diabetes space, and we look forward to their involvement in potentially bringing our device to market,” CEO Sean Saint said in prepared remarks.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.